, Volume 38, Issue 1, pp 27–31 | Cite as

Efficacy of Interleukin-1 Targeting Treatments in Patients with Familial Mediterranean Fever

  • Pinar Cetin
  • Ismail SariEmail author
  • Betul Sozeri
  • Ozlem Cam
  • Merih Birlik
  • Nurullah Akkoc
  • Fatos Onen
  • Servet Akar


Herein, we reported our experience in colchicine-resistant familial Mediterranean fever (FMF) patients who are treated with anti-interleukin-1 (IL-1) drugs. A retrospective review of medical records of anti-IL-1 recipients was performed. The main clinical characteristics of these patients and the evolution after anti-IL-1 were recorded. There were 20 patients (11 male [M] and 9 female [F]). Despite regular colchicine treatment, median number of attacks per month and per year was 1 (1–4) and 12 (4–50), respectively. Twelve patients were receiving anakinra, and eight patients were treated with canakinumab. The number of monthly and yearly attacks after IL-1 treatment was significantly decreased after the biologic agent (p < 0.05). One patient did not respond to the treatment, and one patient developed serious infection during anti-IL-1. We also observed a significant decrease in proteinuria in the amyloidosis complicated FMF patients. Anti-IL-1 targeting drugs seem safe and effective therapies in colchicine-resistant FMF.


familial Mediterranean fever colchicine anakinra canakinumab rilonacept interleukin-1 receptor antagonist protein amyloidosis 


Conflict of Interest

There are no conflicts of interest for any of the authors.


  1. 1.
    Sari, I., M. Birlik, and T. Kasifoglu. 2014. Familial Mediterranean fever: An updated review. European Journal of Rheumatology 1(1): 21–33.CrossRefGoogle Scholar
  2. 2.
    Kasifoglu, T., S.Y. Bilge, I. Sari, D. Solmaz, S. Senel, H. Emmungil, L. Kilic, S.Y. Oner, F. Yildiz, S. Yilmaz, et al. 2014. Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: A multicentre study. Rheumatology (Oxford) 53(4): 741–745.CrossRefGoogle Scholar
  3. 3.
    Mankan, A.K., A. Kubarenko, and V. Hornung. 2012. Immunology in clinic review series; focus on autoinflammatory diseases: Inflammasomes: Mechanisms of activation. Clinical and Experimental Immunology 167(3): 369–381.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Ozkurede, V.U., and L. Franchi. 2012. Immunology in clinic review series; focus on autoinflammatory diseases: Role of inflammasomes in autoinflammatory syndromes. Clinical and Experimental Immunology 167(3): 382–390.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Ben-Chetrit, E., and H. Ozdogan. 2008. Non-response to colchicine in FMF–definition, causes and suggested solutions. Clinical and Experimental Rheumatology 26(4 Suppl 50): S49–S51.PubMedGoogle Scholar
  6. 6.
    Hashkes, P.J., S.J. Spalding, E.H. Giannini, B. Huang, A. Johnson, G. Park, K.S. Barron, M.H. Weisman, N. Pashinian, A.O. Reiff, et al. 2012. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: A randomized trial. Annals of Internal Medicine 157(8): 533–541.CrossRefPubMedGoogle Scholar
  7. 7.
    Meinzer, U., P. Quartier, J.F. Alexandra, V. Hentgen, F. Retornaz, and I. Kone-Paut. 2011. Interleukin-1 targeting drugs in familial Mediterranean fever: A case series and a review of the literature. Seminars in Arthritis and Rheumatism 41(2): 265–271.CrossRefPubMedGoogle Scholar
  8. 8.
    Ozen, S., Y. Bilginer, N. Aktay Ayaz, and M. Calguneri. 2011. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. Journal of Rheumatology 38(3): 516–518.CrossRefPubMedGoogle Scholar
  9. 9.
    Stankovic Stojanovic, K., Y. Delmas, P.U. Torres, J. Peltier, G. Pelle, I. Jeru, M. Colombat, and G. Grateau. 2012. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrology, Dialysis, Transplantation 27(5): 1898–1901.CrossRefPubMedGoogle Scholar
  10. 10.
    Akgul, O., E. Kilic, G. Kilic, and S. Ozgocmen. 2013. Efficacy and safety of biologic treatments in familial Mediterranean fever. American Journal of the Medical Sciences 346(2): 137–141.CrossRefPubMedGoogle Scholar
  11. 11.
    Grattagliano, I., L. Bonfrate, V. Ruggiero, G. Scaccianoce, G. Palasciano, and P. Portincasa. 2014. Novel therapeutics for the treatment of familial Mediterranean fever: From colchicine to biologics. Clinical Pharmacology and Therapeutics 95(1): 89–97.CrossRefPubMedGoogle Scholar
  12. 12.
    Livneh, A., P. Langevitz, D. Zemer, N. Zaks, S. Kees, T. Lidar, A. Migdal, S. Padeh, and M. Pras. 1997. Criteria for the diagnosis of familial Mediterranean fever. Arthritis and Rheumatism 40(10): 1879–1885.CrossRefPubMedGoogle Scholar
  13. 13.
    Pras, M. 1998. Familial Mediterranean fever: From the clinical syndrome to the cloning of the pyrin gene. Scandinavian Journal of Rheumatology 27(2): 92–97.CrossRefPubMedGoogle Scholar
  14. 14.
    Dinarello, C.A., S.M. Wolff, S.E. Goldfinger, D.C. Dale, and D.W. Alling. 1974. Colchicine therapy for familial Mediterranean fever. A double-blind trial. New England Journal of Medicine 291(18): 934–937.CrossRefPubMedGoogle Scholar
  15. 15.
    Zemer, D., M. Revach, M. Pras, B. Modan, S. Schor, E. Sohar, and J. Gafni. 1974. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. New England Journal of Medicine 291(18): 932–934.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Pinar Cetin
    • 1
  • Ismail Sari
    • 1
    Email author
  • Betul Sozeri
    • 2
  • Ozlem Cam
    • 2
  • Merih Birlik
    • 1
  • Nurullah Akkoc
    • 1
  • Fatos Onen
    • 1
  • Servet Akar
    • 3
  1. 1.Department of RheumatologyDokuz Eylul University School of MedicineIzmirTurkey
  2. 2.Department of PediatricsEge University School of MedicineIzmirTurkey
  3. 3.Department of RheumatologyKatip Celebi University School of MedicineIzmirTurkey

Personalised recommendations